GlassScriptPhysician profile
Jonathan W Bekenstein
NPI 1649298266
$37,061.72
in general payments reported to CMS, 2019-2025
59 companies · $2,329 in 2025
The $2,329 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,488 · 2021: $1,922 · 2022: $2,536 · 2023: $9,668 · 2024: $3,376 · 2025: $2,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,578 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,540 · Travel and Lodging: $971 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,577.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,540.00 |
| Travel and Lodging | $970.52 |
| Education | $285.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $27,940.59 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Abbvie INC. | $1,011.51 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Biogen, INC. | $909.85 | 2021-2025 | Tysabri, Vumerity, Leqembi |
| Alexion Pharmaceuticals, INC. | $578.92 | 2022-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $392.25 | 2021-2025 | Mavenclad, Mavenclad |
| Lilly USA, LLC | $388.28 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Novartis Pharmaceuticals Corporation | $374.75 | 2021-2025 | |
| Ceribell, INC. | $371.76 | 2025 | Pocket Eeg Device |
| Eisai INC. | $348.71 | 2022-2025 | |
| Amgen INC. | $344.17 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $341.50 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Sk Life Science, INC. | $296.91 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $187.88 | 2022-2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $186.73 | 2022-2024 | |
| Grifols USA, LLC | $174.92 | 2023-2025 | Gamunex-C |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $174.75 | 2024-2025 | |
| Horizon Therapeutics Plc | $174.20 | 2022-2023 | Uplizna |
| Genzyme Corporation | $173.90 | 2019-2024 | |
| Kyowa Kirin, INC. | $173.44 | 2021-2024 | Nourianz |
| Neurelis, INC. | $173.39 | 2022-2025 | Valtoco |
| Celgene Corporation | $168.28 | 2022-2025 | Zeposia |
| Pfizer INC. | $167.80 | 2023-2025 | |
| Lundbeck LLC | $146.39 | 2022-2024 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $129.25 | 2022-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $126.90 | 2022-2023 | Xarelto |
| Amneal Pharmaceuticals LLC | $115.54 | 2022-2025 | Rytary, Crexont |
| Axsome Therapeutics, INC. | $111.69 | 2023-2025 | Sunosi, Symbravo |
| Banner Life Sciences, LLC | $100.96 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $98.43 | 2022 | |
| Sumitomo Pharma America, INC. | $83.06 | 2023-2024 | Aptiom |
| Impel Pharmaceuticals INC. | $74.32 | 2023 | Trudhesa |
| Csl Behring | $68.20 | 2022-2025 | Hizentra |
| Janssen Biotech, INC. | $57.13 | 2025 | |
| Sunovion Pharmaceuticals INC. | $56.46 | 2022 | |
| Octapharma USA, INC. | $53.24 | 2023-2024 | Panzyga |
| Neurocrine Biosciences, INC. | $52.99 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $52.71 | 2025 | Rexulti |
| Argenx US, INC. | $49.14 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Harmony Biosciences LLC | $44.91 | 2023 | Wakix |
| Cycle Pharmaceuticals INC | $41.60 | 2024 | Tiopronin, Tascenso Odt |
| Catalyst Pharmaceuticals, INC. | $40.50 | 2023-2024 | Fycompa |
| Acorda Therapeutics, INC | $40.36 | 2022-2024 | Inbrija, Ampyra |
| Corium, LLC | $40.27 | 2023 | Adlarity |
| Vanda Pharmaceuticals INC. | $39.72 | 2024-2025 | Ponvory |
| Life Molecular Imaging LTD | $38.61 | 2025 | Neuraceq |
| Averitas Pharma INC. | $35.23 | 2025 | Qutenza |
| Boston Scientific Corporation | $33.12 | 2025 | Watchman Flx |
| Livanova USA, INC. | $32.19 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alnylam Pharmaceuticals INC. | $32.18 | 2023-2024 | Onpattro |
| Acadia Pharmaceuticals INC | $28.89 | 2023-2024 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $28.60 | 2024 | Wainua |
| Avanir Pharmaceuticals, INC. | $26.05 | 2022 | |
| Mallinckrodt Hospital Products INC. | $25.44 | 2023 | Acthar |
| Mdd US Operations, LLC | $19.81 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.89 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.16 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.76 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $15.83 | 2025 | Lumryz |
| Ge Healthcare | $14.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bekenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.